About
He also acted as the company’s Chairman from November 2009 until March 2011, when the company was acquired by Amgen for up to $1bn ($425m upfront). BioVex (now a subsidiary of Amgen) is based in Woburn, MA, USA and Abingdon, UK and develops biologics for solid tumours and prophylactic vaccines for infectious diseases. The Company’s lead program is completing Phase III testing for metastatic melanoma (study fully enrolled). Philip’s key responsibilities and achievements at Biovex include the successfully implemented exit strategy; the sale to Amgen represented one of the largest takeovers of a private VC backed biotech company in recent years. In 2005, Philip established Biovex’ US operations from scratch; recruiting the entire US senior management team (outside the CTO) whilst setting up all key functions including commercial capabilities. Arriving as the first employee in the US he grew the Company to 70 employees in Woburn, MA while retaining 30 in Abingdon, UK. Over the years,
Position in the VCSift Database
- • 2,490 investors hold the Founder role in VCSift. Philip Sparke is one of them.
- • 18 investors are based in Weston, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Weston, US
Contact Information
Find more investors like Philip
Search Investors